Skip to content

Medical emergency? What to do

Generic Drug Makers May Get a Boost in Market

3-RXPublished October 25, 20052 min read

Key points

  • This has been a lackluster year for the stocks of generic drug makers, but that's about to change.
  • The drug maker in the best position to benefit from these changes is an Israeli company called Teva Pharmaceutical Industries.
  • Teva is seeking approval for versions of 140 existing brand-name drugs, including 37 that would qualify as first-to-market products.
  • Fears that a price war will trim profit margins have been a drag on shares of generic-drug manufacturers.

This has been a lackluster year for the stocks of generic drug makers, but that's about to change.

In the next five years, drugs representing more than $100 billion in U.S. sales will lose patent protection. A generic drug may be sold once the original manufacturer's patent expires. The first company to market a generic equivalent typically gets six months' sales exclusivity.

The drug maker in the best position to benefit from these changes is an Israeli company called Teva Pharmaceutical Industries. Founded in Jerusalem 104 years ago to distribute imported drugs, Teva is now the largest seller of generic pharmaceuticals in the United States, with a 13 percent market share.

Teva's market share will approach 20 percent once it completes its proposed acquisition of U.S. generics maker Ivax. That $7.4 billion cash-and-stock deal, announced in July, should close late this year or early next. With a market capitalization of $21 billion, Teva is the largest company on the Tel Aviv Stock Exchange and trades on Nasdaq as symbol TEVA.

Teva is seeking approval for versions of 140 existing brand-name drugs, including 37 that would qualify as first-to-market products. Ivax adds another 65 applications, although some overlap Teva's, plus generic versions of the antidepressant Zoloft and prostate treatment Proscar that will launch next year with six months' sales exclusivity.

Generics account for about 54 percent of all U.S. drug sales. Investment bank SG Cowen expects that to rise to 58 percent after the new Medicare drug program launches in January. The plan will allow seniors to purchase prescription-drug coverage from private insurers, which are expected to push generic drugs aggressively to keep costs down.

Fears that a price war will trim profit margins have been a drag on shares of generic-drug manufacturers. Although Teva's stock is up 11 percent this year, to $33 in mid-August, its price-earnings ratio of 23 -- based on the previous four quarters of profits -- is near an all-time low, says analyst Richard Watson of investment bank William Blair. He says that Teva shares could trade closer to $40 next year once those fears subside.

"I think a lot of the concern that the party will be spoiled in '06 and '07 is overdone," Watson says.

Teva trades at 21 times the average of analysts' 2005 earnings estimates of $1.56 per share, according to Thomson First Call.

Source: Deseret News (Salt Lake City)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.